CJC-1295 / Ipamorelin: Research Overview

The short version

CJC-1295/Ipamorelin is not one compound but a research combination of two: CJC-1295, a long-acting analog of growth-hormone-releasing hormone (GHRH), and ipamorelin, a small peptide that activates a completely different receptor — the one ghrelin (the "hunger hormone") normally uses. Because the two peptides trigger growth hormone release through independent biological pathways, researchers have long been interested in whether combining them produces a bigger effect than either alone.

The honest caveat up front: no controlled human trial has ever tested this specific two-peptide combination. Everything said about it here is built from each peptide's separate research record, plus older laboratory work on how the two receptor pathways interact when activated together. Neither peptide is FDA-approved, and both are sold only as research chemicals. This page describes what is actually known, what is inferred, and what community reports say anecdotally — clearly labeled as such.

What it is

CJC-1295 is the GHRH-analog half of the pair — a modified version of hGRF(1-29) that, in its usual "DAC" form, is chemically bonded to serum albumin for a multi-day duration of action; a shorter-acting "no-DAC" version (also called Modified GRF 1-29) omits that bond and lasts only minutes to hours. Ipamorelin is a synthetic five-amino-acid peptide — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — derived from an earlier compound (GHRP-1) by removing two of its amino acids, which selectively activates the ghrelin/growth-hormone secretagogue receptor (GHS-R1a).

Because the two peptides are sold and dosed separately, "CJC-1295/Ipamorelin" describes a combination protocol rather than a single manufactured molecule — and which CJC-1295 variant (DAC or no-DAC) is being paired matters a great deal, since the two have very different durations of action.

How it works

CJC-1295 binds the GHRH receptor on pituitary somatotroph cells, activating a Gs-protein/cyclic-AMP pathway that drives GH synthesis and release. Ipamorelin binds a different receptor on the same cells — GHS-R1a — activating a separate signaling route through intracellular calcium. Because these are two distinct receptors with two distinct intracellular pathways, laboratory work in cells engineered to express both receptors found that activating them together produced a cyclic-AMP response roughly twice as large as activating the GHRH receptor alone — a receptor-level explanation for why combining the two is thought to produce a larger GH pulse than either compound alone ^[10].

The practical effect researchers describe is a GH pulse that layers CJC-1295's sustained baseline elevation underneath ipamorelin's sharper, shorter spike. But because CJC-1295 (DAC) can keep GH elevated for days while ipamorelin's own effect lasts only hours, the net exposure produced by any specific dosing schedule is not something the research directly characterizes — it is inferred from the two separate pharmacological profiles.

What the research shows

No study has enrolled subjects on the fixed CJC-1295/ipamorelin combination itself. What exists instead is single-compound pharmacology plus one piece of receptor-interaction evidence. The most direct mechanistic support is older cell-based work showing that co-activating cloned GHRH and ghrelin receptors produced roughly double the cyclic-AMP signal of GHRH-receptor activation alone ^[10]. On the CJC-1295 side, the core human data are the same 2006 studies discussed on CJC-1295's own page: single subcutaneous doses in healthy adults produced 2- to 10-fold GH increases lasting six or more days and 1.5- to 3-fold IGF-1 increases lasting 9-11 days ^[4], and the underlying DAC-albumin chemistry was established in rats, where it produced a 4-fold increase in GH output over unconjugated peptide ^[7].

A useful piece of read-across context, though it is not about this combination directly, comes from a 2026 meta-analysis of five randomized trials of tesamorelin — a different GHRH analog — which found significant reductions in visceral fat (-27.71 cm2) and hepatic fat (-4.28%), and increased lean mass (+1.42 kg), with no serious adverse events ^[8]. It illustrates what GHRH-receptor stimulation of the GH/IGF-1 axis can do in a controlled setting, even though it was not conducted on CJC-1295 or on this combination. A broader review of GH secretagogues as a drug class found them generally well tolerated, with increased blood glucose from reduced insulin sensitivity as the chief safety concern, and flagged that long-term cancer-incidence and mortality data are still needed across the class ^[9].

Reported effects, cautions & safety

Reported effects (anecdotal, not clinical evidence): deeper, more restorative sleep is the single most-cited benefit of this combination in research-use community reports, often noticed within one to two weeks of a pre-bed protocol. Faster workout recovery and less soreness are also frequently described, often grouped with other "recovery stack" peptides in community write-ups. Gradual fat loss and a leaner look over five or more weeks, increased appetite in the hours after dosing (attributed by the community mainly to the ipamorelin half, since it acts on the ghrelin receptor), and improvements in skin, mood, or energy are reported less consistently. None of this comes from a controlled study of the combination.

On the downside, injection-site redness or mild swelling and transient water retention are the most consistently mentioned complaints, generally described as milder than with older-generation GH-releasing peptides. A brief facial flush or "head rush" in the minutes after injecting, tingling or carpal-tunnel-like hand symptoms, and grogginess or lightheadedness are reported less often.

Cited safety cautions: because GH raises IGF-1 — a growth factor that promotes cell proliferation — researchers flag active or recent malignancy as a theoretical, mechanism-based concern; this reasoning draws on CJC-1295's own dose-dependent GH/IGF-1 data ^[4] but has never been tested for this combination specifically. A published review of GH secretagogues identifies increased blood glucose from reduced insulin sensitivity as the class's chief metabolic concern, which is the same reasoning that applies to fluid retention, carpal-tunnel-type symptoms, and cardiovascular vulnerability in people with pre-existing edema-prone or cardiac conditions ^[9]. Most fundamentally, researchers are direct about the biggest caution here: the fixed blend has never been evaluated in any controlled trial, and its two components act on very different timescales — CJC-1295 (DAC) produces a multi-day GH/IGF-1 elevation ^[4][7], while ipamorelin's own effect is a single short pulse — so the net GH exposure produced by any specific research protocol is not something the literature has directly characterized.

Where it fits in the Growth Hormone Axis

This page sits at the intersection of the guide's two mechanisms. CJC-1295 supplies the GHRH-receptor half and ipamorelin supplies the ghrelin-receptor half; this combination is the research community's attempt to engage both at once. Tesamorelin, the fourth compound here, is a reminder of how far a GHRH analog can go through a conventional, FDA-supervised trial program — a contrast worth keeping in mind when reading about an untested combination. See the full picture on the comparison page.